尿激酶在急性心肌梗死溶栓中安全性的评价

The Evaluation of Safety of UK in AMI Thrombolysis

目的:通过分析79例急性心肌梗死(AMI)溶栓后出血和再灌注心律失常并发症的发生率,评价尿激酶(UK)在AMI溶栓中安全性。方法:选择符会溶栓疗法参考方案的AMI病人,按方案标准用UK进行溶栓治疗,观察再通率与两种并发症的发生率。结果:79例病人中,再通56例,再通率70.9%。并发症情况:出血5例,占6.3%,且为轻度出血,再灌注心律失常8例,占10.1%,主要是室性心律失常。结论:用UK对AMI病人实施静脉溶栓时并发症尤其是致命性并发症的发生率低,适用于基层医院。

Objective：To evaluate the safety of urokinase （UK） in acute myocardial infarction（AMI） thrombolysis by analyzing the incidence of 79 cases of AMI bleeding and reperfusion arrhythmia complications after thrombolysis.Methods：Select the patients who meet the reference program of thrombolytic therapy, conduct the thrombolytic therapy with UK by program standard and observe recanalization rate and the incidence of two complications.Results：There were 56 with recanalization out of 79 cases and the recanalizafion rate was 70.9%. Conclusion：The rate of complicatons,especially fatal complication is low when implementing Intravenous thrombolysis therapy to patients,and that method is appropriate for basic hospital.